Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

Compounded semaglutide has emerged as a significant development in the management of obesity and type 2 diabetes. As a ...

In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.

In the 28-day DIO study, mice treated with the HT-6184 and semaglutide combination experienced a notable increase in weight loss. Combining HT-6184 with a subtherapeutic dose of semaglutide (1 nmol/kg ...

Among patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...

Semaglutide injections effectively support weight loss by regulating appetite and glucose levels, offering benefits for ...

Representational Photo The exploration of novel peptides for their potential impact on metabolic pathways has been a ...

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, ...

The House and Senate are racing to complete the government funding process with the Sept. 30 shutdown deadline looming and lawmakers eager to head back to their districts to campaign ahead of the ...

A new study, led by Professor John Deanfield from University College London (UCL), reveals that the anti-obesity medication ...

Few medications have become as popular and culturally relevant as Ozempic has, but how exactly do it and similar drugs affect ...

MADRID — The benefits of semaglutide treatment in reducing kidney disease, cardiovascular, and mortality risks in people with ...